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2DIABETES MELLITUS

β-Cell Dysfunction

INSULIN
HOLDS TRUE
FOR
TYPE 1 D.M.
3Adapted from WHO Diabetes Programme Facts and Figures:
www.who.int/diabetes/facts/world_figures/en. Accessed 1 August, 2006.
Worldwide prevalence of 
diabetes in 2000
Number of persons
< 5,000
5,000–74,000
75,000–349,000
350,000–1,499,000
1,500,000–4,999,000
> 5,000,000
No data available
4Worldwide prevalence of 
diabetes in 2030 (projected)
Total cases > 300 million adults
Number of persons
< 5,000
5,000–74,000
75,000–349,000
350,000–1,499,000
1,500,000–4,999,000
> 5,000,000
No data available Adapted from WHO Diabetes Programme Facts and Figures:
www.who.int/diabetes/facts/world_figures/en. Accessed 1 August, 2006. 
5Type 2 diabetes: a growing problem
 A serious, progressive disease, characterized 
by two fundamental defects
 Insulin resistance
 β-cell dysfunction
 Accounts for > 95% on diabetes cases worldwide
 Represents a significant disease burden
 Associated with serious microvascular and macrovascular 
complications
 Significant impact on overall healthcare costs
6Characteristics of type 2 diabetes
 Chronic hyperglycaemia with disturbances 
of carbohydrate, fat and protein 
metabolism
 Defects in insulin action (insulin 
resistance), insulin secretion (β-cell 
dysfunction) or both
7O.H.A. are the most common form of treatment of Type 2
D.M. worldwide. When used judiciously they are important
agents in the management of the most common form of
Diabetes.
ORAL HYPOGLYCEMIC AGENTS
8For economic, logistic and general
effectiveness, oral agents are a
dependable means of treating a
large population of diabetics world
wide when used correctly
O. H. A.
9ORAL HYPOGLYCEMIC AGENTS
SULFONYLUREAS
BIGUANIDES
MEGLITINIDES
ALPHA GLUCOSIDASE INHIBITORS
THIAZOLIDINEDIONES
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CLINICAL BARRIERS TO O.H.A.S.
HYPOGLYCEMIA
DIURNAL GLUCOSE FLLUCTUATIONS
EXECESSIVE WEIGHT GAIN
POST PRANDIAL HYPERGLYCEMIA
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Ideal Therapeutic Agents
• improve the timing and amount of insulin 
secreted without unduly stressing the 
already maximally stimulated beta-cells
• enhance insulin actions
• restore inhibition of hepatic gluconeogensis 
to normal
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SULPHONYLUREAS
FIRST GENERATION
Tolbutamide
Chlorpropamide
CH2 -CH2CH2CH2CH2
Cl                      -CH2CH2CH2
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SULPHONYLUREAS
SECOND GENERATION
Gliclazide
GLIBENCLAMIDE
GLIPIZIDE
CH3- - N
CH2CH2
NH
C = O
H
OCH3
CI
CH2CH2 H
NH
C = O
N
N
CH3
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EFFECTS OF SULPHONYLUREAS
• Increased tissue sensitivity to insulin thus improved 
insulin action
• Reduced hepatic extraction of insulin from the 
circulation
• Effects on plasma lipids, i.e. Triglycerides and 
Cholesterol, Direct effects unlikely
• Effects on platelets and fibrinolysis
• Effects on Basement Membrane to reduce thickness
17
SULFONYLUREAS:
EXTRAPANCREATIC EFFECTS
1. Increased insulin receptor binding sites
2. Decreased hepatic gluconeogenesis. 
Augmentation of insulin-induced 
suppression of hepatic glucose release.
3. Inhibition of triglyceride lipase
4. Enteroinsular axis stimulation
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OPTIONS FOR SULFONYLUREAS
CHLORPROPAMIDE
TOLBUTAMIDE
GLIBENCLAMIDE
GLIPIZIDE
GLICLAZIDE
GLIMEPIRIDE
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BIGUANIDES 
MODE OF ACTION
 Inhibition of glucose and aminoacid transport 
across small bowel
 Enhanced glycolysis in extra hepatic tissues
 Inhibition of hepatic gluconeogenesis
 Direct cellular effect 
 Increase in glucose uptake
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BIGUANIDES 
MODE OF ACTION
 In isolated mitochodria there is intereference with transfer of
high energy bonds to A.D.P. suggesting that the compound
inhibits oxidative phosphorylation.
 1/3 is eliminated as metabolite. 2/3 is eliminated unchanged.
30% is excreated in urine in 5 hours and 90% in 24 hours.
 Toxicity associated with hypoxia, renal insufficiency and
excessive alcohol intake.
 Hypoglycemia due to phenformin alone is actually unknown.
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BIGUANIDES 
CONTRA-INDICATIONS
 Patients with renal insufficiency
 Conditions that predispose to tissue hypoxia.
 Severely uncontrolled diabetes
 C.C.F., I.H.D., Malignant hypertension, Proliferative 
retinopathy
 Pulmonary insufficiency
 Acute infections, traumatic or inflammatory conditions
 Advanced age.
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BIGUANIDES 
CONTRA-INDICATIONS
 Hepatic dysfunction (hepatitis, cirrhosis, fatty liver)
 Alcohol abuse
 Patients using barbiturates, salicylates 
phenothiazines
 General debilitating conditions
 Pre and post operatively (1 week)
 During starvation diet
 Poorly complying patients
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OPTIONS FOR BIGUANIDES
 Phenformin
 Metformin
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NEWER O.H.A.
• GUAR GUM
• ACARBOSE
• GLIMEPIRIDE
• REPAGLINIDE
• GLITAZONES
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ACARBOSE
 Inhibits Glucosidase Activity
 GI Effects
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• Less Hypos
• Less Weight gain
• Less Hyperinsulinemia
• Less early failure of cells
• Less skipped doses
GLIMEPIRIDE
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INSULIN SECRETAGOGUES
Miglitinide Analog – Repaglinide
• No peripheral effects on muscle, liver and adipose tissue
• Excreted via bite – safe in patients with renal disease
• Lower risk for hypoglycemia even on skipping a meal!
• Good efficacy & safety profile even in the elderly
• First line therapy in type 2 patients with diet failure
• Good results when used in combination with Metformin
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REPAGLINIDE
• Non Sulfonylurea
• Insulinotropic agent
29
GLITAZONES
Modes of Action
• It activates the nuclear peroxisome proliferator 
activated receptor - (PPAR- )
• It also has partial agonist activity against PPAR 
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DIFFERENT TYPES OF PPARS
Tissue Skeletal muscle Not Adipose tissue, skeletal,
expression liver, kidney known cardiac muscle, liver, kidney SI,
bladder & spleen
Function Control of lipoprotein Not Adipocyte differentiation
metabolism, fatty acid known
oxidation
Target Actions Treatment of dyslipidemia Not Improves insulin sensitivity 
known
Natural ligands Docosahexanoic acid Not PG metabolite PGJ,
known
Synthetic ligand Fibrates - Thiazolidinediones
Also expressed in vascular endothelial cells, VSMC & monocytes /macrophages
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GLITAZONES
• INHIBITS SMOOTH MUSCLE CELLS (SMC) 
PROLIFERATION IN PATIENTS WITH INSULIN 
RESISTANCE
• LIVER CELL INJURY IN 1.9% CASES IN CONTROLLED 
TRIALS
• SUBFULMINANT LIVER FAILURE
• RETENTION OF FLUID
• ANEMIA
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GLITAZONES
• INCREASES INSULIN SENSITIVITY IN SKELETAL 
MUSLCE, HEPATIC AND ADIPOSE TISSUE
• DECREASES ENDOGENOUS INSULIN 
CONCENTRATION
• DECREASES EXOGENOUS INSULIN REQUIREMENTS
• INDUCES CYTOCHROME p 450 ISOENZYME 3 A 4
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Characteristics of Oral Antidiabetic Agents
Efficacy Insulin 
secretagogues
Metformin -Glucosidase 
inhibitors
Insulin TZDs
Effect on FPG / HbA1C
Effect on Plasma insulin -
Effect on insulin 
resistance
- /- - -
Effect on β-cell function - - - -
Safety and tolerability
Risk of hypoglycaemia  - -  -
Weight gain  - -  
Gastrointestinal side-
effects
-   - -
Lactic acidosis -  - - -
Oedema - - - - 
Effiacy : = reduced levels; = increased levels; - = no documented change. Safety and 
tolerability :  = treat-related adverse event; - no documented association with 
treatment. FPG = fasting plasma glucose. TZDs = thiazolidinedions.
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TYPE 2 DIABETES MELLITUS
SECONDARY FAILURE
• Secondary failure rate 5% to 10% a year (UKPDS 
7% a year)
• Decreasing -cell function
• Obesity
• Non-adherence to treatment
• Lack of exercise
• Intercurrent illness
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PROBALITY OF REQUIRING 
POLYTHERAPY
• Young age at diagnosis
• Increased base line Obesity
• Increased base line Glycemia
• Increased baseline Triglycerides
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TRADITIONAL STEPWISE APPROACH
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EARLY COMBINATION APPROACH. 
OAD, ORAL ANTIDIABETIC DRUG
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ADVANTAGES OF FIXED DOSE 
COMBINATIONS
 Improved compliance
 Synergism
 Enhanced efficacy
 Reduction of side effects
 Economy
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DR. ELLIOT JOSLIN
GOALS OF THERAPY
FOR THOSE WITH DIABETES MELLITUS
SHOULD INCLUDE A SERIOUS EFFORT
TO
ACHIEVE BLOOD GLUCOSE LEVELS
AS CLOSE TO NORMAL AS POSSIBLE
CONFIRMED BY
DCCT
UK PDS
KUOMOTO TRIAL
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 Combination Efficacy, Safety, Tolerability.
 Metformin
 Thiazolidinediones
IDEAL O.H.A.
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ADA “Consensus” on Type 2 Diabetes Therapy
Nonpharmacologic
Therapy
Diet
Exercise
Monotherapy
Sulfonylureas
Biguanides
-Glucosidase inhibitors
Glitazones
Meglitinides
Insulin
Combination Therapy
Frequently used or well studied
Sulfonylurea + Metformin
Sulfonylurea + Troglitazone
Sulfonylurea + Pioglitazone
Sulfonylurea + Acarbose
Repaglinide + Metformin
Rosiglitazone + Metformin
Sulfonylurea + Insulin
Metformin + Insulin
Pioglitazone + Insulin
Troglitazone + Insulin
Acarbose + Insulin
Infrequently used and/or 
less well studies
Sulfonylurea + Metformin + Troglitazone
Sulfonylurea + Metformin + Insulin
Troglitazone + Metformin + Insulin
Glycemic 
goals 
not 
achieved
Insulin
Intermediate BID
Intermediate + Regular BID
Multiple (3 or more) injections
Glycemic goals not 
achieved
Very symptomatic
Severe hyperglycemia
Ketosis
Unrecognized IDDM
Pregnancy
Glycemic goals 
not achieved
Modified from Zimmerman et al. Diabetes Care - 1995.
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PRACTICAL MANAGEMENT OF TYPE 2 
DIABETES MELLITUS
126-140 mg/dL 140-200 mg/dL 200-240 mg/dL 240-300 mg/dL > 300 mg/dL
Glitazones
Metformin
Acarbose
Acarbose
Repaglinide
Metformin
Metformin
Sulfonylurea
No Sx Sx No Sx/Sx No Sx Sx
Sulfonylurea
Glitazones
Sulfonylurea Sulfonylurea Sulfonylurea Insulin
FBG>126
“All get diet and exercise”
Monotherapy
Oral Combination
• Evolving criteria
• If FBG>140 mg/dL (126 mg/dL?)
• HbA1c > 8% (7%?)
• Add second oral agent and
titrate to maximum dose
Triple Therapy
• If no improvement:
• Try a different sensitizer
• Or try triple therapy?
• Or Continue oral agent(s)
and add insulin Rx at PM or Hs
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CONCLUSION
• MONOTHERAPY
• COMBINATION THERAPY
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THANK YOU
